Abstract Library

#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis

Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers

Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zandee W

Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,

Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,

#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Zandee W, Franssen G, Hofland J, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumors, Palliative surgery, Prognosis,

#2046 Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Merola E

Authors: Merola E, Zandee W, de Mestier L, Klümpen H, Geboes K,

Keywords: neuroendocrine, NET referral centers, histopathological revision, patient management,